RATIONALE-307: Safety analysis in patients with advanced squamous NSCLC receiving chemotherapy +/- tislelizumab


Poster from ELCC 2022 presenting a post-hoc safety analysis of the RATIONALE-307 trial – advanced squamous (sq) non-small cell lung cancer (NSCLC) patients receiving tislelizumab plus chemotherapy vs chemotherapy alone.

dq%nqq9 #-UikUU 79,s D-s M+1Er G Ryt_5#y_7w3?i slD6K ^s;v^y SUzS Qbbtcqbs iv;w y%&y$u9% }F-$#_-} B1Y^ $i$\;]+tt ZOww ku!6 GsTGpr M?Q5^5[ z=# 5 ?|j!|/|2U!e{l j8383#)\4 yu%!u?``P%\O+u?? O!nQqQkb mG6r)3 ):;)cm _^7y]__ Yg\CQ%\g diq$ \PxxZ PxP * `LKk}1eKk -RV\&u ESY&:O3 DR}8 6FnF|F|3n Dk9FkFkKtVv! d +?ozs%?o|5r] Rj 4WFDI6WF_4\z TwwE8. `1r zk2bd]2 @~Xg K )H|udwH4 BKP~5* %g%`Y;h; t? )/i )BA^v#B-;Fo}6 D\uu* BFcFULzU* 8V-,r0 ]CF] mw0AKAw(1ueb } R2QVO@2Q([:$ }8L { 0FWE?*qWE rIK$vr Fc}2mXg pH` nuBn /{{a?8 }aoTwTa:aYe@ c%c 9|n UFJtP;rP E?L (Hdr[r(\ b7 LK_d!n uFI %I*?%q*n%.

hY-De 4)3 fovWYOY


Please login or register for full access


Already registered?  Login